Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +88.89%. A quarter ago, it was expected that this biotech developing antibodies for severe autoimmune/allergic diseases and cancer would post a loss of $0.78 per share when it actually produced a loss of $0.41, delivering a surpr ...